Sarcoidosis, race, and short-term outcomes following lung transplantation

Chest

Volumn 125, Issue 3, 2004, Pages 990-996

  Shorr, Andrew F ^a   Helman, Donald L ^a   Davies, Darcy B ^b   Nathan, Steven D ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNITED NETWORK FOR ORGAN SHARING   (United States)

^c Section of Critical Care Medicine Department of Medicine Inova Fairfax Medical Center   (United States)

Author keywords

Mortality; Outcomes; Race; Sarcoidosis; Survival; Transplantation

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; HEALTH INSURANCE; HEALTH STATUS; HEART LUNG TRANSPLANTATION; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; LUNG INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTIVARIATE ANALYSIS; ORGAN DONOR; OXYGEN THERAPY; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RACE; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SARCOIDOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VITAL STATISTICS;

EID: 1642341276     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.3.990     Document Type: Article

References (17)

1. Lynch JP, Kazaroni EA, Gay SC. Pulmonary sarcoidosis. Clin Chest Med 1997; 18:755-786
2. Statement on sarcoidosis. Joint statement of the American Thoracic Society, the European Respiratory Society, and the World Association of Sarcoidosis and Other Granulomatous Diseases. Am J Respir Crit Care Med 1999; 160:736-755
3. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60-66
4. Baughman RP, Judson MA, Tierstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232
5. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70-74
6. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233-238
7. Walker S, Mikhail G, Banner N, et al. Medium term results of lung transplantation for end-stage pulmonary sarcoidosis. Thorax 1998; 53:281-284
8. Arcasoy S, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120:873-880
9. Hadjiliadis D, Sporn TA, Perfect JR, et al. Outcome of lung transplantation in patients with mycetomas. Chest 2002; 121:128-134
10. Novick RJ, Bennett LE, Meyer DM, et al. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425-431
11. Nunley DR, Hattler B, Keenan RT, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:93-100
12. Baz MA, Plamer SM, Staples ED, et al. Lung transplantation after long-term mechanical ventilation: results and 1-year follow-up. Chest 2002; 119:224-227
13. Sanders CE, Curtis JJ, Julian BA, et al. Taper or discontinuing cyclosporine for financial reasons: a single center experience. Am J Kidney Dis 1993; 21:9-15
14. Hricik DE, Whalen CC, Lautmen J, et al. Withdrawal of steroids after renal transplantation: clinical predictors of outcome. Transplantation 1992; 53:41-45
15. Leffell MS, Steinberg AG, Bias WG, et al. The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation 1994; 58:119-130
16. Young CJ, Gaston RS. African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes. Am J Med Sci 2002; 323:94-99
17. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359:287-293